Comparison of endothelial function in patients with Stage I-II arterial hypertension and stable angina, receiving various bradycardic agents and perindopril
- Р Р‡.МессенРТвЂВВВВВВВВжер
- РћРТвЂВВВВВВВВнокласснРСвЂВВВВВВВВРєРСвЂВВВВВВВВ
- LiveJournal
- Telegram
- ВКонтакте
- РЎРєРѕРїРСвЂВВВВВВВВровать ссылку
Full Text:
Abstract
Aim. To compare endothelial function in patients with Stage I-II arterial hypertension (AH) and Functional Class (FC) II stable angina, receiving either beta-adrenoblocker (metoprolol tartrate) or If channel inhibitor (ivabradine), combined with perindopril.
Material and methods. In total, 77 patients and 26 healthy volunteers were examined. The patients received either perindopril and metoprolol, or perindopril and ivabradine for 24 weeks. At baseline, and after 12 and 24 weeks, endothelial function (EF) was assessed by plasma levels of von Willebrand factor, vWF and brachial artery reactive hyperemia test.
Results. In patients with Stage I-II AH and FC II stable angina, EF disturbances were manifested in reduced vasomotor function and increased vWF levels, comparing to the controls. Both therapeutic combinations improved EF and decreased the levels of EF markers, elevated at baseline. The combination of perindopril and ivabradine demonstrated greater and earlier EF normalization.
Conclusion. The combination of perindopril and ivabradine, as well as perindopril and metoprolol, showed beneficial effects on EF. This beneficial effect was greater and earlier for perindopril and ivabradine combination, which could be due to greater vasoprotection by ivabradine than by metoprolol combined with perindopril.
About the Authors
L. L. KirichenkoRussian Federation
Moscow
A. N. Golosova
Russian Federation
Moscow
S. V. Gatsura
Russian Federation
Moscow
A. P. Korolev
Russian Federation
Moscow
K. V. Ovsyannikov
Russian Federation
Moscow
P. V. Struchkov
Russian Federation
Moscow
References
1. Karpov Yu.A., Shal'nova S.A., Deev A.A. ot imeni uchastnikov programmy. Issledovanie PREM''ERA: dostizhenie tselevogo urovnya arterial'nogo davleniya - uspekh v lechenii ishemicheskoi bolezni serdtsa. Kardiovask ter profil 2006; 6: 53-60.
2. Shal'nova S.A., Deev A.D., Karpov Yu.A ot imeni uchastnikov programmy PREM''ERA. Arterial'naya gipertoniya i IBS v ambulatornoi praktike vrachakardiologa. Kardiovask ter profil 2006; 2:73-80.
3. Buval'tsev V.I. Disfunktsiya endoteliya kak novaya kontseptsiya profilaktiki i lecheniya serdechno-sosudistykh zabolevanii. Mezhdunar med zhurn 2001; 3: 202-8.
4. Vorob'eva E.N., Shumakher G.I., Osipova I.V.i dr. Rol' disfunktsii endoteliya v patogeneze ateroskleroza. Kardiovask ter profil 2006; 6: 129-36.
5. Ageev F.T. Rol' endotelial'noi disfunktsii v razvitii i progressirovanii serdechno-sosudistykh zabolevanii. Serd nedostat 2003; 4: 22.
6. GIllum R, Makuc D, Feldman J. Pulse rate, coronary heart dIsease, and death: The NHANES I epIdemIologIc follow-up study. Am Heart J 1991; 121: 172-7.
7. WIlhelmsen L, Berlund G, Elmfeldt D, et al. The multIfactor prImary preventIon trIal In Geteborg, Sweden. Eur Heart J 1986; 7: 279-88.
8. Karpov Yu.A., Buza V.V. Ivabradin kak novaya sostavlyayushchaya effektivnogo lecheniya bol'nykh stabil'noi stenokardiei. Serdtse 2006; 5: 248-52.
9. DIaz A, Bourassa MG, GuertIn MC, et al. Long-term prognostIc value of restIng heart rate In patIents wIth suspected or proven coronary artery dIsease. Eur Heart J 2005; 26 (10): 96774.
10. ParentI A, FIllIpI S, AmerInI S, et al. InosItol phosphate metabolIsm and nItrIc-oxIde synthase actIvIty In endothelIal cells are Involved In the vasorelaxant actIvIty of nebIvolol. J Pharmacol Exp Ther 2000; 292: 698-703.
11. The EUROPA InvestIgators. EffIcacy of perIndoprIl In reductIon of cardIovascular events among patIents wIth stable coronary artery dIsease: randomIsed, double-blInd, placebo-controlled, multIcentre trIal (the EUROPA study). Lancet 2003; 362; 782-8.
12. Celermajer D, Sorensen K, Gooch V, et al. Non-InvasIve detectIon of endothelIal dysfunctIon In chIldren and adults at rIsk of atherosclerosIs. Lancet 1992; 340: 1111-5.
13. Thompson SG, KIenast J, Pyke SD, et al. HemostatIc factors and the rIsk of myocardIal InfarctIon or sudden death In patIents wIth angIna pectorIs. NEJM 1995; 332: 635-41.
14. Remme WJ. EUROPA: perIndoprIl’s benefIts accordIng to blood pressure and endothelIal functIon In coronary artery dIsease. Oral presentatIon. A SatellIte SymposIum held durIng the ESC. Congress MunIch 2004.
15. Telejko E. PerIndoprIl argInIne: benefIts of a new salt of the ACE InhIbItor perIndoprIl. Curr Med Res OpIn 2007; 23(5): 953-60.
16. LekakIs J, Protogerou A, PapamIchael Ch, et al. Effect of nebIvolol and atenolol on brachIal artery flow-medIated vasodIlatIon In patIents wIth coronary artery dIsease. CardIovasc Drugs Ther 2005; 19: 277-81.
17. ThorIn E, ThorIn-Trescases N. Vascular endothelIal ageIng, heartbeat after heartbeat. CardIovasc Res 2009; 84: 24-32.
18. CustodIs F, Baumhakel M, SchlImmer N, et al. Heart rate reductIon by IvabradIne reduces oxIdatIve stress, Improves endothelIal functIon, and prevents atherosclerosIs In apolIpoproteIn E-defIcIent mIce. CIrculatIon 2008; 117: 2377-87.
Review
For citations:
Kirichenko L.L., Golosova A.N., Gatsura S.V., Korolev A.P., Ovsyannikov K.V., Struchkov P.V. Comparison of endothelial function in patients with Stage I-II arterial hypertension and stable angina, receiving various bradycardic agents and perindopril. Cardiovascular Therapy and Prevention. 2009;8(7):25-30. (In Russ.)
ISSN 2619-0125 (Online)